Authors: Alexandre Demoule, Amandine Baptiste, Arnaud W. Thille, Thomas Similowski, Stephanie Ragot, Gwénael Prat, Alain Mercat, Christophe Girault, Guillaume Carteaux, Thierry Boulain, Sébastien Perbet, Maxens Decavèle, Lisa Belin, Jean-Pierre Frat
Categories: Research, Acute respiratory failure, Dyspnea, High-flow oxygen therapy, Intubation, Mortality
Dyspnea is a key symptom of de novo acute hypoxemic respiratory failure. This study explores dyspnea and its association with intubation and mortality in this population.
This was a secondary analysis of a multicenter, randomized, controlled trial. Dyspnea was quantified by a visual analog scale (dyspnea-VAS) from zero to 100 mm. Dyspnea was measured in 259 of the 310 patients included. Factors associated with intubation were assessed with a competing risks model taking into account ICU discharge. The Cox model was used to evaluate factors associated with 90-day mortality.
At baseline (randomization in the parent trial), median dyspnea-VAS was 46 (interquartile range, 16–65) mm and was ≥ 40 mm in 146 patients (56%). The intubation rate was 45%. Baseline variables independently associated with intubation were moderate (dyspnea-VAS 40–64 mm) and severe (dyspnea-VAS ≥ 65 mm) dyspnea at baseline (sHR 1.96 and 2.61, p = 0.023), systolic arterial pressure (sHR 2.56, p < 0.001), heart rate (sHR 1.94, p = 0.02) and PaO2/FiO2 (sHR 0.34, p = 0.028). 90-day mortality was 20%. The cumulative probability of survival was lower in patients with baseline dyspnea-VAS ≥ 40 mm (logrank test, p = 0.049). Variables independently associated with mortality were SAPS 2 ≥ 25 (p < 0.001), moderate-to-severe dyspnea at baseline (p = 0.073), PaO2/FiO2 (p = 0.118), and treatment arm (p = 0.046).
In patients admitted to the ICU for de novo acute hypoxemic respiratory failure, dyspnea is associated with a higher risk of intubation and with a higher mortality.
Trial registration: clinicaltrials.gov Identifier # NCT 01320384.
The online version contains supplementary material available at 10.1186/s13054-024-04903-5.
Keywords: Dyspnea, High-flow oxygen therapy, Mortality, Intubation, Acute respiratory failure
Acute respiratory failure (ARF) results from an imbalance between the load and the capacity of the respiratory system. Noninvasive respiratory support such as high flow oxygen therapy (HFOT) and noninvasive ventilation (NIV) may prevent intubation by reducing load capacity imbalance and hence signs of respiratory distress [1, 2]. Early prediction of the need for intubation in patients with de novo hypoxemic ARF remains challenging. Many factors supposed to predict intubation, such as severe hypoxemia, shock or coma, are themselves actually intubation criteria [3–7]. The best prediction accuracy of the ratio of respiratory-rate-oxygenation index is after 12 h of HFOT [8]. Tidal volume is also a good predictor of intubation, but only in patients receiving NIV [5, 9, 10].
Dyspnea, the abnormal and distressing awareness of breathing, is a key symptom of ARF [11]. As opposed to physical signs of respiratory distress such as tachypnea and labored breathing, dyspnea is a symptom, which places a very strong emphasis on self-reporting [11]. Because it parallels respiratory drive, dyspnea is a marker of load capacity imbalance [12]. As such, dyspnea could help to predict intubation. Reports on dyspnea as a predictor of intubation are scarce. In patients receiving NIV for ARF of a mixed nature, dyspnea was associated with adverse outcomes, including NIV failure [13]. Similar results were observed in COVID-19 patients [14]. Of note, dyspnea was among intubation criteria of only one of the large randomized controlled trials published in the last decade and in which intubation was the primary or a major secondary outcome [1, 15–19]. The reason why dyspnea has been so little studied is unclear.
Here, we performed a post hoc analysis of a large scale multicenter, randomized controlled trial in which dyspnea was measured [1]. Our first objective was to quantify the prevalence and intensity of dyspnea in non-intubated patients receiving noninvasive respiratory support (either standard oxygen, HFOT or NIV delivered by an ICU ventilator) for de novo hypoxemic ARF and to examine factors associated with dyspnea. Our second objective was to investigate the association between dyspnea and intubation. Finally, we examined the association between dyspnea and mortality. Our hypotheses were that dyspnea was frequent and severe in this population, and that a more intense dyspnea was associated with a higher risk of intubation and mortality.
We performed a post hoc analysis of a randomized, controlled trial (NCT 01320384, registered on 22 March 2011) conducted in 23 centers in France and Belgium [1]. In this study, 310 patients admitted to ICU with ARF were randomly assigned to receive a treatment by standard oxygen, HFOT or NIV delivered by an ICU ventilator. All patients had a respiratory rate > 25 breaths/min, a ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) ≤ 300 mm Hg and a PaCO2 ≤ 45 mmHg. The main exclusion criteria were severe neutropenia, acute-on-chronic respiratory failure, cardiogenic pulmonary edema, shock or altered consciousness. The original parent trial was approved by ethics committees at Centre Hospitalier Universitaire de Poitiers for French study sites (n. 10.11.28, 28 December 2010) and at Cliniques Universitaires Saint-Luc, Brussels for the site in Belgium (n. 10.07.12, 3 May 2011). Written informed consent was obtained from all the patients, their next of kin or another surrogate decision-maker as appropriate. According to French law, this post hoc analysis of the original study did not need additional ethics approval as no more data were collected for this analysis. Procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as most recently amended. Two other post hoc analyses of this study have been already published [9, 21].
Clinical variables, respiratory variables and blood gas samples were collected at two time points. First, at randomization in the original parent trial, during spontaneous breathing with a non-rebreathing mask, termed “baseline” in the present post hoc analysis. Second, 1 h after initiation of the allocated treatment by the randomization in the parent trial (standard oxygen, HFOT or NIV) [1]. To assess the intensity of dyspnea, patients were asked to rate their breathing discomfort (in French “inconfort respiratoire”) by placing a cursor on a 100 mm visual analog scale (dyspnea-VAS) bounded on the left by “no respiratory discomfort” and on the right by “worst imaginable respiratory discomfort.” Of notice, this question did not target discomfort associated with the respiratory interface. Dyspnea-VAS was used to identify four groups of no dyspnea (dyspnea-VAS < 16 mm), mild dyspnea (dyspnea-VAS between 16 and 39 mm), moderate dyspnea (dyspnea-VAS between 40 and 64 mm), and severe dyspnea (dyspnea-VAS ≥ 65 mm). The 40 mm cutoff was based on the 2024 European Respiratory Society/European Society of Intensive Care Medicine joint statement on dyspnea in critically ill patients [11] and on the many similar features shared by dyspnea and pain (noxious sensations, common pathways, similar cortical areas involved and affective dimension) [22]. The 16 mm and 65 mm cutoffs were based on the first and third quartile of dyspnea-VAS at baseline in our cohort.
The need for invasive mechanical ventilation was defined in the original parent trial by the following prespecified criteria for endotracheal (1) signs of persisting or worsening respiratory failure, including at least two of the following respiratory rate above 40 breaths/min, lack of improvement of signs of high respiratory muscle workload, development of copious tracheal secretions, pH below 7.35, or SpO2 below 90% for more than 5 min; (2) hemodynamic instability; or (3) deterioration of neurologic status [1]. Of note, dyspnea was not among these criteria. Intensive care unit mortality and 90-day mortality were recorded.
Quantitative variables were described as median (interquartile range). Qualitative variables were described as frequency (percentages). Five outcomes were two qualitative outcomes, dyspnea at baseline and dyspnea 1 h after randomization, one quantitative outcome, the difference between dyspnea intensity at baseline and dyspnea 1 h after randomization and two censored outcomes, time from enrollment to intubation (with discharge from ICU as a competitive event) and 90-day mortality, defined as the time from enrollment to death. Patients alive at 90 days were censored at 90 days, and patients lost to follow-up were censored to their last known contact.
Factors associated with moderate-to-severe dyspnea at baseline and after the first hour were studied by multivariate logistic regression analysis. The multivariate model was built with the following variables that were considered to be clinically age, smoker, immunosuppression status, McCabe score, heart rate, systolic arterial pressure, respiratory rate, bilateral pulmonary infiltrates, PaO2/FiO2 and randomization arm in the parent trial (oxygenation strategy). Adjusted odds ratios (OR) were presented with their 95% confidence intervals (CI). Factors associated with the change in dyspnea intensity between baseline and the first hour were studied using a multivariable linear regression model, taking into account the same variables as well as dyspnea intensity at baseline.
Factors associated with time to intubation were studied using the Fine and Gray model with ICU discharge as a competing event [23]. Cumulative incidence of intubation was estimated with the Kalbfleisch and Prentice method, considering ICU discharge as a competing event [24]. These factors were compared using Gray’s test [25]. A first multivariate model was built with the following baseline variables that were considered to be clinically SAPS 2, randomization arm, bilateral pulmonary infiltrates, heart rate, systolic arterial pressure, respiratory rate, dyspnea and PaO2/FiO2 at baseline. A second multivariate model was built with the following variables that were considered to be clinically relevant 1 h after treatment heart rate, arterial pressure, respiratory rate, dyspnea and PaO2/FiO2 and change in dyspnea between baseline and 1 h after treatment initiation. Adjusted subdistribution hazard ratios (sHR) were presented with their 95% CI.
Finally, the association between dyspnea and 90-day mortality was evaluated with a Cox proportional hazard model. Cumulative incidence curves for mortality were estimated using the Kaplan–Meier estimator and compared using a log rank test. The multivariate model was built with the following variables that were considered to be clinically age, preexisting cardiac failure, immunosuppression, McCabe score, SAPS 2 on admission, SOFA score on inclusion, randomization arm, bilateral pulmonary infiltrates and dyspnea at baseline. Adjusted hazard ratios (HR) were presented with their 95% CI.
For each model, validity assumptions were checked (log-linearity and proportional hazards assumptions) and multivariate models were built using a backward selection based on AIC (Akaike information criterion) criteria.
Analyses were conducted at the two-sided α risk of 5%. No multiplicity test correction was made. All statistical analyses were performed with R statistical software, version 3.2.0 (available online at http://www.r-project.org/ and package survival, cmprsk).
Among the 313 patients included in the parent trial, three patients withdrew consent and quantification of dyspnea was missing in 51 patients at baseline and in 57 patients 1 h after treatment initiation (see Additional file 1 Figure E1). Table 1 indicates the patient characteristics at baseline.
At baseline, the intensity of dyspnea was 46 (16–65) mm on the dyspnea-VAS (Fig. 1) and dyspnea was mild (dyspnea-VAS between 16 and 39 mm) in 17% of patients, moderate (dyspnea-VAS between 40 and 64 mm) in 32% and severe (dyspnea-VAS ≥ 65 mm) in 24%. After 1 h of treatment, the intensity of dyspnea score decreased to 35 (10–56) mm (p = 0.0004) (Fig. 1) and was mild in 22% of patients, moderate in 30% and severe in 17%. The median absolute variation of dyspnea was 10 (0–20) mm and decreased by 10 mm or more in 219 (51%) patients.
Fig. 1 Box plots showing dyspnea-visual analog scale from zero (no respiratory discomfort) to 100 mm (worst imaginable respiratory discomfort) at baseline and 1 h after treatment initiation. The black center line denotes the median value (50th percentile), while the box contains the 25th to 75th percentiles of dataset. The blue line denotes the mean value. The black whiskers mark the maximal and minimal values
Table 1 displays the factors associated with mild, moderate and severe dyspnea at baseline. On multivariate logistic regression analysis, three factors were independently associated with reduced risk of moderate-to-severe dyspnea (dyspnea-VAS ≥ 40 mm) at smoking (OR 0.39, 95% CI 0.22–0.69), immunosuppression (OR 0.48, 95% CI 0.25–0.92) and McCabe 2 or 3 (OR 0.32, 95% CI 0.16–0.65).
Table 2 shows the factors associated with mild, moderate and severe dyspnea 1 h after treatment initiation. On multivariate logistic regression analysis, six of these factors were independently associated with moderate-to-severe dyspnea (dyspnea-VAS ≥ 40 mm) 1 h after treatment initiation. Four factors were associated with increased risk of moderate-to-severe age > 60 years (OR 2.17, 95% CI 1.20–3.90), systolic arterial pressure 1 h after treatment initiation (OR per 10 points increased 1.13 95% CI 0.98–1.30), respiratory rate 1 h after treatment initiation (OR per 10 points increased 1.43 95% CI 0.96–2.13) and bilateral pulmonary infiltrates (OR 3.08, 95% CI 1.42–6.65). Two factors were associated with reduced risk of moderate-to-severe immunodeficiency (OR 0.49, 95% CI 0.25–0.97) and HFOT (OR 0.57, 95% CI 0.34–0.95).
On multivariable linear regression model, two factors were associated with the change in dyspnea-VAS between baseline and 1 h after treatment dyspnea-VAS at baseline (− 0.38 ± 0.05, p < 0.001) and noninvasive respiratory support (− 7.09 ± 3.35 for HFOT and 2.56 ± 3.36 for noninvasive ventilation as compared to standard oxygen, p = 0.011) (Additional file 1, Table E1). There was no difference between treatment groups at baseline in terms of dyspnea intensity. However, 1 h after treatment initiation, dyspnea-VAS decreased in the HFOT group, while it did not change in the two other groups (Additional file 1, Table E2).
This analysis excluded three do-not-intubate patients who died without being intubated. The intubation rate was 45% (n = 115).
Table 3 displays the baseline variables associated with intubation while accounting for ICU discharge as a time-dependent competing risk. On Fine and Gray’s multivariate regression analysis, four variables were independently associated with intubation (Table 3). Three variables were associated with a higher risk of moderate (dyspnea-VAS 40–64 mm) and severe (dyspnea-VAS ≥ 65 mm) dyspnea at baseline (sHR 1.96, 95% CI 1.07–3.57 and sHR 2.61, 95% CI 1.40–4.87), baseline systolic arterial pressure 120–140 mmHg (sHR 2.56, 95% CI 1.58–4.17) and heart rate > 100 beat/min at baseline (sHR 1.94, 95% CI 1.29–2.92). One variable, baseline PaO2/FiO2 > 200 mmHg (sHR 0.34, 95% CI 0.15–0.76), was associated with a lower risk of intubation. The cumulative incidence of intubation was higher in patients with moderate-to-severe dyspnea at baseline than in those with no or mild dyspnea (p = 0.0004) (Fig. 2). There was no significant interaction between dyspnea and the randomization group (p = 0.071).
Fig. 2 Cumulative incidence of intubation (solid line) while accounting for intensive care unit discharge (dashed line) among patients with no dyspnea at baseline (blue line), mild dyspnea (red line), moderate dyspnea (black line) and severe dyspnea (green line)
The variables measured 1 h after treatment initiation that were associated with a higher risk of intubation on Fine and Gray’s multivariate regression analysis were severe dyspnea (dyspnea-VAS ≥ 65 mm), high respiratory rate, high arterial blood pressure, high heart rate. A high PaO2/FiO2 1 h after treatment initiation was associated with a lower risk of intubation (Additional file 1, Table E3).
Intensive care unit mortality was 18% (n = 46), and 90-day mortality was 20% (n = 53). Ninety-day mortality was 16% (n = 11) in patients with no dyspnea, 16% (n = 6) in patients with mild dyspnea, 20% (n = 17) in patients with moderate dyspnea and 31% (n = 19) in patients with severe dyspnea (p = 0.110). Figure 3 shows the cumulative probability of survival up to 90 days in patients with no, mild, moderate and severe dyspnea (logrank test, p = 0.086). The cumulative probability of survival was lower in patients with baseline dyspnea-VAS ≥ 40 mm (logrank test, p = 0.049) (see Additional file 1, Figure E2).
Fig. 3 Cumulative survival up to 90 days in patients with no dyspnea at baseline (blue line), mild dyspnea (red line), moderate dyspnea (black line) and severe dyspnea (green line)
On the multivariate Cox proportional hazard model, three factors remained in the final model and were associated with an increased 90-day SAPS 2 ≥ 25, moderate-to-severe dyspnea at baseline, PaO2/FiO2 and treatment arm (Table 4).
In this ancillary study of patients admitted to the ICU for acute de novo hypoxemic ARF and treated either by noninvasive respiratory support, (1) the intensity of dyspnea at baseline was high, (2) moderate and severe dyspnea at baseline were independently associated with the risk of intubation, (3) moderate-to-severe dyspnea at baseline was also associated with 90-day mortality.
To the best of our knowledge, this is the largest study to investigate dyspnea in a population of non-intubated patients admitted for de novo hypoxemic ARF. Dyspnea has been measured as a secondary outcome in many trials [26–30] and has also been measured in a large heterogeneous population of patients receiving NIV [13]. However, the prevalence of dyspnea and its risk factors and prognostic impact have not been previously studied in a large and homogeneous population.
A major finding of our study is that poor respiratory comfort was independently associated with intubation, which has been previously reported in patients receiving NIV for ARF, for COVID-19, and in those with chronic obstructive pulmonary disease exacerbation [13, 14, 31]. This may be considered as an obvious finding, since the intensity of dyspnea is a marker of ARF severity and subsequently a symptom that physicians integrate into their intubation decision-making process. However, as opposed to signs of respiratory distress that are observed by the physician [32], dyspnea is a symptom that can only be self-reported by the patient. No study has scientifically evaluated this hypothesis, and we are not aware of physicians clearly asking their patients whether they are dyspneic or not when intubation is considered. In addition, in our study, dyspnea per se was not one of the prespecified criteria of intubation in the parent trial [1]. Subsequently, dyspnea was not supposed to be taken into account by the physician when she or he decided to intubate the patient. Dyspnea was also associated with higher mortality in our study, reinforcing the belief that dyspnea is a proxy for the severity of ARF [33]. This is in line with previous studies showing an association between poor respiratory comfort and hospital mortality in patients with suspected acute myocardial infarction [34, 35], in those admitted for acute COPD exacerbation [36] and even in patients without previously diagnosed cardiopulmonary diseases [37–39]. Dyspnea is associated with a higher intubation rate in COVID-19 patients [14], and dyspnea upon hospital discharge is also associated with higher risk of readmission or death [40, 41].
Our study highlighted the high intensity of dyspnea in patients managed for ARF in the ICU, with around half of patients reporting dyspnea of an intensity ≥ 40 mm. Similar pain intensity corresponds to the three most painful procedures experienced by ICU patients [42], and these patients should receive analgesia promptly [22]. Dyspnea can be considered as a key feature of ARF, and therefore, it is not surprising to observe such a high level of dyspnea in these patients. However, it should deserve consideration and should be managed and be controlled rapidly, like pain, to mitigate the immediate suffering and anxiety that are strongly associated with dyspnea [13, 43]. Indeed, dyspnea rated as ≥ 30/100 mm is considered to be unacceptable by one third of patients [44]. Moreover, dyspnea is involved in the dark recollections of patients following their ICU stay [45, 46] and contributes to the pathogenesis of post-traumatic stress disorders [47]. Without doubt, the relief of dyspnea is currently considered by some authors to be a basic human right [48, 49]. Educational actions are needed to ensure that identification and management of dyspnea are performed as routinely as for pain. A previous study has shown that detection of moderate-to-severe dyspnea by nurses was not followed by any therapeutic intervention, in contrast to the detection of pain, which was significantly associated with the administration of opioids [50]. There is also an urgent need to develop and validate clinical approaches to relieve dyspnea independently from the correction of its cause, exactly as in the case of pain [49].
The major strengths of our study are the prospective collection of data, especially for dyspnea level, the prespecified intubation criteria that did not include dyspnea and the multicenter design. This study presents limitations that need to be acknowledged. First, we quantified respiratory comfort at only two time points, at baseline and after 1 h. A longitudinal analysis based on multiple repeated measurements could provide additional results [31]. However, a substantial proportion of patients were intubated in the first hours of management, which causes a significant drop-off. Second, patients were not systematically assessed for delirium, which may affect the self-reporting of dyspnea. However, dyspnea was not collected in patients who were unable to provide clear and coherent answers. Third, patients were asked to quote their breathing discomfort, which is not exactly dyspnea. Although terms such as “feeling breathlessness,” “shortness of breath” or “troubles breathing,” and “getting enough air” could have been used, none of them reflects perfectly dyspnea and a recent statement recognizes “breathing discomfort” as a proxy for dyspnea [11].
In conclusion, this study showed that dyspnea is frequent and of a high intensity in a large proportion of critically ill patients with de novo hypoxemic ARF. Moderate-to-severe dyspnea is associated with poor outcomes and seems to be a threatening signal in these patients. As this symptom is easy to identify at the bedside, dyspnea could become a variable that is measured on a regular basis, like respiratory rate and pain intensity. Future studies are needed to evaluate the benefit of this systematic measurement on patient management and post ICU burden. Future studies should also develop strategies to relieve dyspnea, exactly as in the case of pain.
Nick Walker has edited the manuscript for English.
AD, AB, LB and JPF designed the study. AD coordinated the study. AD, GP, AM, CG, GC, TB, SP, AT, JPF and TS were responsible for patient screening, enrollment and follow-up. AD, AB, SR, LB and MD analyzed the data. AD, TS and JPF wrote the manuscript. All authors contributed to draft the manuscript or revised it critically for important intellectual content and approved the final version of the manuscript. AD, AB, LB and JPF had full access to all of the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis, including and especially any adverse effects.
This work was supported by a grant from the French Ministry of Health.
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
The original parent trial was approved by ethics committees at Centre Hospitalier Universitaire de Poitiers for French study sites (n. 10.11.28, 28 December 2010) and at Cliniques Universitaires Saint-Luc, Brussels for the site in Belgium (n. 10.07.12, 3 May 2011). Written informed consent was obtained from all the patients, their next of kin or another surrogate decision-maker as appropriate. According to French law, this post hoc analysis of the original study did not need additional ethics approval as no more data were collected for this analysis. Procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as most recently amended.
Not applicable.
A Demoule reports grants from French Ministry of Health, Assistance publique—Hôpitaux de Paris, Lungpacer, Respinor, consulting fees from Respinor, Lungpacer, Lowenstein, Tribunal administrative de Cergy, Liberate Medical, Payment or honoraria for lectures, presentations from Fisher & Paykel, Baxter, Getinge, Astra, Agence Européenne Informatique, Mindray, support for attending meetings and/or travel from Lungpacer, outside the submitted work. A Baptiste has nothing to disclose. AW Thille reports payment or honoraria for lectures, presentations Fisher & Paykel, GE Healthcare, Philips, support for attending meetings and/or travel Fisher & Paykel, GE Healthcare, outside the submitted work. T Similowski reports grants from Lungpacer, consulting fees from ADEP Assistance, AstraZeneca France, Chiesi France, KPL consulting, Lungpacer Inc., Novartis France, TEVA France, Vitalaire, outside the submitted work. S Ragot has nothing to disclose G Prat has nothing to disclose A Mercat has nothing to disclose. C Girault reports payment or honoraria for lectures, presentations from Air Liquide Medical System, Medtronic, Dräger, support for attending meetings and/or travel from Fisher & Paykel, GE healthcare, Air Liquide Medical System, outside the submitted work. G Carteau reports payment or honoraria for lectures, presentations Air Liquide Medical System Medtronic Dräger, support for attending meetings and/or travel from Air Liquide Medical System outside the submitted work. T Boulain has nothing to disclose. S Perbet has nothing to disclose. L Belin has nothing to disclose. JP Frat reports non-financial support from Fisher and Paykel Healthcare (the firm provided material and equipment to all the participating centers), grant from the French Ministry of Heath, AADAIRC, French society of intensive care for the parent study, grants from the French Ministry of Heath, Fisher and Paykel Healthcare, consulting fees from SOS Oxygene, payment or honoraria for lectures from Fisher and Paykel Healthcare, support for attending meetings and/or travel from Fisher and Paykel Healthcare and SOS Oxygene, outside the submitted work.
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.